Matches in Nanopublications for { ?s ?p "[The frequency of TAP1, LMP2 and tapasin loss varied between 33% of primary adenocarcinomas, 40% of HIN to approximately 67% of metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- NP723013.RAVOzocdzDVZXOJZPd11_y1ifZjpJ0149urP5SquY8Fws130_assertion description "[The frequency of TAP1, LMP2 and tapasin loss varied between 33% of primary adenocarcinomas, 40% of HIN to approximately 67% of metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP723013.RAVOzocdzDVZXOJZPd11_y1ifZjpJ0149urP5SquY8Fws130_provenance.
- assertion description "[The frequency of TAP1, LMP2 and tapasin loss varied between 33% of primary adenocarcinomas, 40% of HIN to approximately 67% of metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP874945.RABfNRthBMPzDwbQFlqNVqh7sbgh6uSuAJz3AO1j6Ee5c130_assertion description "[The frequency of TAP1, LMP2 and tapasin loss varied between 33% of primary adenocarcinomas, 40% of HIN to approximately 67% of metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP874945.RABfNRthBMPzDwbQFlqNVqh7sbgh6uSuAJz3AO1j6Ee5c130_provenance.
- NP429964.RAeuVYl5tVbyLbrr6MG_UO-kjioigcbZ6U_rTGooDYyUk130_assertion description "[The frequency of TAP1, LMP2 and tapasin loss varied between 33% of primary adenocarcinomas, 40% of HIN to approximately 67% of metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP429964.RAeuVYl5tVbyLbrr6MG_UO-kjioigcbZ6U_rTGooDYyUk130_provenance.
- NP429965.RAcicJyzqnuyZ8134Z0f7BmFvCS-tY6koDYSxPnrQNIOo130_assertion description "[The frequency of TAP1, LMP2 and tapasin loss varied between 33% of primary adenocarcinomas, 40% of HIN to approximately 67% of metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP429965.RAcicJyzqnuyZ8134Z0f7BmFvCS-tY6koDYSxPnrQNIOo130_provenance.
- NP429966.RAMgi_RinByTqG3rsd1ayCA8ZSplls8DDcIFz8b6ihrOs130_assertion description "[The frequency of TAP1, LMP2 and tapasin loss varied between 33% of primary adenocarcinomas, 40% of HIN to approximately 67% of metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP429966.RAMgi_RinByTqG3rsd1ayCA8ZSplls8DDcIFz8b6ihrOs130_provenance.
- NP722769.RA6Uz-k8F7rW_vQ935CauyBSnmJQ3Bn7fA1rpRX6o2nGA130_assertion description "[The frequency of TAP1, LMP2 and tapasin loss varied between 33% of primary adenocarcinomas, 40% of HIN to approximately 67% of metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP722769.RA6Uz-k8F7rW_vQ935CauyBSnmJQ3Bn7fA1rpRX6o2nGA130_provenance.
- NP722850.RAziAk5jprCbiGl6Y8Ic8WdZDT7wepN6FYva6l5RG0Ag8130_assertion description "[The frequency of TAP1, LMP2 and tapasin loss varied between 33% of primary adenocarcinomas, 40% of HIN to approximately 67% of metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP722850.RAziAk5jprCbiGl6Y8Ic8WdZDT7wepN6FYva6l5RG0Ag8130_provenance.
- NP722984.RAwnSNcIMjHHhtK-FQ3Gb1ugkLS9i2H1QSSDFPPYypBwk130_assertion description "[The frequency of TAP1, LMP2 and tapasin loss varied between 33% of primary adenocarcinomas, 40% of HIN to approximately 67% of metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP722984.RAwnSNcIMjHHhtK-FQ3Gb1ugkLS9i2H1QSSDFPPYypBwk130_provenance.
- NP722998.RA_y8GDlMbnslpmU7ECqSFQvxZeG94fbanFrRch3MQLVI130_assertion description "[The frequency of TAP1, LMP2 and tapasin loss varied between 33% of primary adenocarcinomas, 40% of HIN to approximately 67% of metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP722998.RA_y8GDlMbnslpmU7ECqSFQvxZeG94fbanFrRch3MQLVI130_provenance.
- NP429968.RA5mLQaiS0ZHrPsQHjB0YGzXZkNPw7FwuaGRVDPKvPGrY130_assertion description "[The frequency of TAP1, LMP2 and tapasin loss varied between 33% of primary adenocarcinomas, 40% of HIN to approximately 67% of metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP429968.RA5mLQaiS0ZHrPsQHjB0YGzXZkNPw7FwuaGRVDPKvPGrY130_provenance.
- NP874790.RA70A7mz5vN6PyVGi85laOv5gGI0FHB6J7AX2czo9C43o130_assertion description "[The frequency of TAP1, LMP2 and tapasin loss varied between 33% of primary adenocarcinomas, 40% of HIN to approximately 67% of metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP874790.RA70A7mz5vN6PyVGi85laOv5gGI0FHB6J7AX2czo9C43o130_provenance.